SOCIAL QUESTIONS|health|medical science
- teiripe T-cheall le gabhdóir ciméarach aintaiginí Reference "Faofa ag an gCoiste Téarmaíochta, www.tearma.ie ;Faomhadh an téarma seo mar chuid de Thionscadal Lex"
- ga
- chimeric antigen receptor T cell therapy | CAR T cell therapy | CAR-T cell therapy | CAR-Tcell therapy
- en
- Definition "type of treatment with CAR T-cells derived from a patient’s own blood (autologous) or derived from a healthy person (allogenic) which are grown in large numbers in the laboratory and then given to the patient by infusion" Reference "COM-Terminology Coordination, based on:Kieran Breen, Chimeric antigen receptor (CAR) T cell therapies (1.2.2021), European Medicines Agency (EMA)"
- Comment Memorial Sloan Kettering Cancer Center (MSK) announced on 14.9.2023 that Michel Sadelain, MD, PhD, renowned physician-scientist, Director of the Center for Cell Engineering, and Stephen and Barbara Friedman Chair, has been awarded the 2024 Breakthrough Prize in Life Sciences. The prestigious prize recognizes Dr. Sadelain and Carl June, MD, of the University of Pennsylvania, for the development of chimeric antigen receptor T cell immunotherapy (CAR T cell therapy) whereby the patient’s T cells are modified to target and kill cancer cells. Dr. Sadelain is a pioneer and leader in the field of immunology, genetic engineering, and the development of CAR T cell therapy. A type of immunotherapy, CAR T cell therapy uses genetically engineered versions of a person’s own immune cells to find and fight cancer.